Amivantamab (original) (raw)
Amivantamab ist ein monoklonaler Antikörper, der als Arzneistoff zur Behandlung bestimmter Formen des nicht-kleinzelligen Lungenkrebses (NSCLC) eingesetzt wird. Für dieses Anwendungsgebiet erhielt er in den USA im Mai 2021, in der EU im Dezember 2021, unter dem Namen Rybrevant (Janssen Biotech) die Zulassung.
| Property | Value |
|---|---|
| dbo:abstract | Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. The most common side effects include rash, infusion-related reactions, skin infections around the fingernails or toenails, muscle and joint pain, shortness of breath, nausea, fatigue, swelling in the lower legs or hands or face, sores in the mouth, cough, constipation, vomiting and changes in certain blood tests. Amivantamab is a bispecific epidermal growth factor (EGF) receptor-directed and mesenchymal–epithelial transition (MET) receptor-directed antibody. It is the first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Amivantamab was approved for medical use in the United States in May 2021, and in the European Union in December 2021. (en) Amivantamab ist ein monoklonaler Antikörper, der als Arzneistoff zur Behandlung bestimmter Formen des nicht-kleinzelligen Lungenkrebses (NSCLC) eingesetzt wird. Für dieses Anwendungsgebiet erhielt er in den USA im Mai 2021, in der EU im Dezember 2021, unter dem Namen Rybrevant (Janssen Biotech) die Zulassung. (de) Амивантамаб — лекарственный препарат, противоопухолевое моноклональное антитело для лечения рака легких. Одобрен для применения: США (2021). (ru) |
| dbo:alternativeName | Rybrevant (en) |
| dbo:casNumber | 2171511-58-1 |
| dbo:class | dbr:Antineoplastic |
| dbo:drugbank | DB16695 |
| dbo:fdaUniiCode | 0JSR7Z0NB6 |
| dbo:kegg | D11894 |
| dbo:wikiPageExternalLink | http://www.fda.gov https://druginfo.nlm.nih.gov/drugportal/name/amivantamab |
| dbo:wikiPageID | 67738863 (xsd:integer) |
| dbo:wikiPageLength | 16830 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1119142111 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Epidermal_growth_factor dbr:Epidermal_growth_factor_receptor dbr:Mesenchymal–epithelial_transition dbr:Non-small_cell_lung_cancer dbr:Indication_(medicine) dbr:International_nonproprietary_name dbr:Intravenous_therapy dbr:Antineoplastic dbr:Committee_for_Medicinal_Products_for_Human_Use dbr:European_Medicines_Agency dbr:Food_and_Drug_Administration dbr:Osimertinib dbc:Breakthrough_therapy dbc:Monoclonal_antibodies_for_tumors dbr:Bispecific_monoclonal_antibody |
| dbp:atcPrefix | L01 (en) |
| dbp:atcSuffix | FX18 (en) |
| dbp:c | 6472 (xsd:integer) |
| dbp:casNumber | 2171511 (xsd:integer) |
| dbp:class | dbr:Antineoplastic |
| dbp:dailymedid | Amivantamab (en) |
| dbp:drugbank | DB16695 (en) |
| dbp:h | 10014 (xsd:integer) |
| dbp:kegg | D11894 (en) |
| dbp:legalCa | Rx-only (en) |
| dbp:legalCaComment | / Schedule D (en) |
| dbp:legalEu | Rx-only (en) |
| dbp:legalUs | Rx-only (en) |
| dbp:mabType | mab (en) |
| dbp:n | 1730 (xsd:integer) |
| dbp:o | 2023 (xsd:integer) |
| dbp:routesOfAdministration | dbr:Intravenous_therapy |
| dbp:s | 46 (xsd:integer) |
| dbp:source | u (en) |
| dbp:synonyms | JNJ-61186372, amivantamab-vmjw (en) |
| dbp:target | Epidermal growth factor receptor and Mesenchymal–epithelial transition (en) |
| dbp:tradename | Rybrevant (en) |
| dbp:type | mab (en) |
| dbp:unii | 0 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:HHS_content dbt:Cite_journal dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:Use_American_English dbt:Use_dmy_dates dbt:Growth_factor_receptor_modulators dbt:ClinicalTrialsGov dbt:Targeted_cancer_therapeutic_agents dbt:Monoclonals_for_tumors |
| dcterms:subject | dbc:Breakthrough_therapy dbc:Monoclonal_antibodies_for_tumors |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody dbo:Drug |
| rdfs:comment | Amivantamab ist ein monoklonaler Antikörper, der als Arzneistoff zur Behandlung bestimmter Formen des nicht-kleinzelligen Lungenkrebses (NSCLC) eingesetzt wird. Für dieses Anwendungsgebiet erhielt er in den USA im Mai 2021, in der EU im Dezember 2021, unter dem Namen Rybrevant (Janssen Biotech) die Zulassung. (de) Амивантамаб — лекарственный препарат, противоопухолевое моноклональное антитело для лечения рака легких. Одобрен для применения: США (2021). (ru) Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. The most common side effects include rash, infusion-related reactions, skin infections around the fingernails or toenails, muscle and joint pain, shortness of breath, nausea, fatigue, swelling in the lower legs or hands or face, sores in the mouth, cough, constipation, vomiting and changes in certain blood tests. Amivantamab was approved for medical use in the United States in May 2021, and in the European Union in December 2021. (en) |
| rdfs:label | Amivantamab (en) Amivantamab (de) Амивантамаб (ru) |
| owl:sameAs | wikidata:Amivantamab dbpedia-de:Amivantamab dbpedia-ru:Amivantamab https://global.dbpedia.org/id/FzUmw |
| prov:wasDerivedFrom | wikipedia-en:Amivantamab?oldid=1119142111&ns=0 |
| foaf:isPrimaryTopicOf | wikipedia-en:Amivantamab |
| is dbo:product of | dbr:Genmab |
| is dbo:wikiPageRedirects of | dbr:Amivantamab-vmjw dbr:Rybrevant |
| is dbo:wikiPageWikiLink of | dbr:Genmab dbr:Amivantamab-vmjw dbr:ATC_code_L01 dbr:Bispecific_monoclonal_antibody dbr:List_of_therapeutic_monoclonal_antibodies dbr:Rybrevant dbr:Treatment_of_lung_cancer |
| is foaf:primaryTopic of | wikipedia-en:Amivantamab |